FDA Will Allow 10 Minor ANDA Corrections Before Refusing To Receive
This article was originally published in The Tan Sheet
Executive Summary
Generic Drug User Fee Act refuse-to-receive draft guidance says FDA will allow sponsors to make a few small fixes to applications, but the agency will not accept any ANDAs with big problems, which will trigger automatic refuse-to-file actions.
You may also be interested in...
First-Cycle Approval Rate Already High; Can PDUFA V Actually Boost It?
FDA official says the rate of approving applications in the first review cycle may not increase much more, even as the new review model, intended to promote more first-cycle approvals, has yet to finish with its inaugural applications.
FDA Tablet Scoring Guidance Holds Brands, Generics To Single Standard
Generic and private label industry concerns that scoring conventions could create barriers to market entry did not win out in the agency’s final tablet scoring guidance. FDA advises firms to contact the agency when questions arise about a product’s scoring being patent-protected.
FDA And Generic Drug Quality: Turning Point, Or Precipice?
OGD Director Geba says generic manufacturers still suffer from extensive quality problems, but GPhA officials argue the industry is doing fine and communications with the agency need to be more uniform.